GEn1E Lifesciences Adds to Development Pipeline with Exclusive Option to License University of Maryland, Baltimore’s MUC1-Ecto-Domain Anti-Bacterial Agent
November 19, 2018 12:30 ET
|
GEn1E Lifesciences Inc.
Provides GEn1E the potential to enter clinic with a therapy for Pseudomonas infections in Cystic Fibrosis patients PALO ALTO, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- GEn1E Lifesciences Inc....
GEn1E Lifesciences Granted Exclusive Option to License University of Maryland, Baltimore’s Selective P38 Kinase Inhibitor
October 17, 2018 09:30 ET
|
GEn1E Lifesciences Inc.
Access to University of Maryland, Baltimore’s broadly applicable P38 Kinase inhibitor technology offers GEn1E the potential to enter the clinic with an acute lung injury/acute respiratory distress...